Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The primary aim of Part A of the study to assess the efficacy and tolerability of GWP42003-P
compared to placebo as an adjunctive treatment for children with Epilepsy with
myoclonic-atonic seizures (EMAS) -associated seizures.
Part B of this study will be conducted to evaluate the long-term safety and tolerability of
GWP42003-P in participants with EMAS.